Loading
A phase 2 trial in lung cancer, run by The First Affiliated Hospital of Guangzhou Medical University, not yet recruiting.
Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study is a phase 2, interventional study registered as NCT07150416 by The First Affiliated Hospital of Guangzhou Medical University, with a registry enrolment figure of 38 participants, started 2025-10-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Recombinant Human Ad-p53 Injection. Conditions listed: Multiple Pulmonary Ground-Glass Nodules; Lung Neoplasms; Precancerous Conditions. Primary outcome: Objective Response Rate (ORR). Sites: China. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.